A randomized clinical trial compared efficacy and toxicity of standard all-trans-retinoic acid (ATRA) plus chemotherapy versus ATRA plus arsenic trioxide in patients with newly diagnosed, low- or intermediate-risk acute promyelocytic leukemia (APL). Here, we report health-related quality-of-life (HRQOL) results.

Efficace, F., Mandelli, F., Avvisati, G., Cottone, F., Ferrara, F., Di Bona, E., Specchia, G., Breccia, M., Levis, A., Sica, S., Finizio, O., Kropp, M., Fioritoni, G., Cerqui, E., Vignetti, M., Amadori, S., Schlenk, R., Platzbecker, U., Lo Coco, F., Randomized phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: health-related quality-of-life outcomes, <<JOURNAL OF CLINICAL ONCOLOGY>>, 2014; 32 (30): 3406-3412. [doi:10.1200/JCO.2014.55.3453] [http://hdl.handle.net/10807/64813]

Randomized phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: health-related quality-of-life outcomes

Sica, Simona;
2014

Abstract

A randomized clinical trial compared efficacy and toxicity of standard all-trans-retinoic acid (ATRA) plus chemotherapy versus ATRA plus arsenic trioxide in patients with newly diagnosed, low- or intermediate-risk acute promyelocytic leukemia (APL). Here, we report health-related quality-of-life (HRQOL) results.
2014
Inglese
Efficace, F., Mandelli, F., Avvisati, G., Cottone, F., Ferrara, F., Di Bona, E., Specchia, G., Breccia, M., Levis, A., Sica, S., Finizio, O., Kropp, M., Fioritoni, G., Cerqui, E., Vignetti, M., Amadori, S., Schlenk, R., Platzbecker, U., Lo Coco, F., Randomized phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: health-related quality-of-life outcomes, <<JOURNAL OF CLINICAL ONCOLOGY>>, 2014; 32 (30): 3406-3412. [doi:10.1200/JCO.2014.55.3453] [http://hdl.handle.net/10807/64813]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/64813
Citazioni
  • ???jsp.display-item.citation.pmc??? 28
  • Scopus 69
  • ???jsp.display-item.citation.isi??? 65
social impact